Sartorius Stedim Biotech S.A. (SDMHF)
USD 201.5
(0.0%)
USD 201.5
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 755.7 Million EUR | -41.41% |
| 2022 | 1.23 Billion EUR | 49.41% |
| 2021 | 798.7 Million EUR | 32.23% |
| 2020 | 569.2 Million EUR | 49.6% |
| 2019 | 416.97 Million EUR | 22.74% |
| 2018 | 349.45 Million EUR | 13.55% |
| 2017 | 275.71 Million EUR | 6.75% |
| 2016 | 280.26 Million EUR | 26.36% |
| 2015 | 213.72 Million EUR | 41.99% |
| 2014 | 156.21 Million EUR | 17.0% |
| 2013 | 129.83 Million EUR | 12.03% |
| 2012 | 113.35 Million EUR | 23.35% |
| 2011 | 96.61 Million EUR | 15.98% |
| 2010 | 83.3 Million EUR | 16.27% |
| 2009 | 71.64 Million EUR | 29.72% |
| 2008 | 55.23 Million EUR | 88.72% |
| 2007 | 29.26 Million EUR | -55.19% |
| 2006 | 65.31 Million EUR | 21.36% |
| 2005 | 53.81 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 187.3 Million EUR | -2.56% |
| 2024 Q1 | 183.6 Million EUR | 14.97% |
| 2024 Q3 | 149.6 Million EUR | -16.38% |
| 2023 Q4 | 108.1 Million EUR | -29.35% |
| 2023 Q3 | 153 Million EUR | -35.2% |
| 2023 Q2 | 236.1 Million EUR | 8.5% |
| 2023 Q1 | 217.6 Million EUR | -20.09% |
| 2023 FY | - EUR | -41.41% |
| 2022 FY | - EUR | 49.41% |
| 2022 Q4 | 272.3 Million EUR | -17.91% |
| 2022 Q1 | 389.5 Million EUR | 1063.59% |
| 2022 Q3 | 331.7 Million EUR | -1.63% |
| 2022 Q2 | 337.2 Million EUR | -13.43% |
| 2021 Q1 | 238.6 Million EUR | 51.94% |
| 2021 Q2 | 253.7 Million EUR | 6.33% |
| 2021 Q3 | 273.1 Million EUR | 7.65% |
| 2021 Q4 | 33.47 Million EUR | -87.74% |
| 2021 FY | - EUR | 32.23% |
| 2020 Q4 | 157.03 Million EUR | -10.78% |
| 2020 Q3 | 176 Million EUR | 33.74% |
| 2020 Q2 | 131.6 Million EUR | 2.65% |
| 2020 Q1 | 128.2 Million EUR | 44.95% |
| 2020 FY | - EUR | 49.6% |
| 2019 Q3 | 103.5 Million EUR | -2.27% |
| 2019 Q4 | 88.44 Million EUR | -14.54% |
| 2019 FY | - EUR | 22.74% |
| 2019 Q2 | 105.9 Million EUR | 10.66% |
| 2019 Q1 | 95.7 Million EUR | -6.14% |
| 2018 Q2 | 86 Million EUR | 22.16% |
| 2018 Q1 | 70.4 Million EUR | 6.33% |
| 2018 FY | - EUR | 13.55% |
| 2018 Q4 | 101.95 Million EUR | 14.56% |
| 2018 Q3 | 89 Million EUR | 3.49% |
| 2017 Q2 | 57.9 Million EUR | -17.17% |
| 2017 FY | - EUR | 6.75% |
| 2017 Q4 | 66.21 Million EUR | -1.91% |
| 2017 Q3 | 67.5 Million EUR | 16.58% |
| 2017 Q1 | 69.9 Million EUR | -5.67% |
| 2016 Q1 | 61.1 Million EUR | 0.37% |
| 2016 Q4 | 74.1 Million EUR | -0.8% |
| 2016 FY | - EUR | 26.36% |
| 2016 Q3 | 74.7 Million EUR | 25.76% |
| 2016 Q2 | 59.4 Million EUR | -2.78% |
| 2015 Q4 | 60.87 Million EUR | -7.62% |
| 2015 Q1 | 50.3 Million EUR | 26.68% |
| 2015 Q2 | 45.9 Million EUR | -8.75% |
| 2015 FY | - EUR | 41.99% |
| 2015 Q3 | 65.9 Million EUR | 43.57% |
| 2014 Q4 | 39.7 Million EUR | 1.29% |
| 2014 Q2 | 30.5 Million EUR | -6.44% |
| 2014 Q3 | 39.2 Million EUR | 28.52% |
| 2014 FY | - EUR | 17.0% |
| 2014 Q1 | 32.6 Million EUR | 0.49% |
| 2013 Q2 | 30.7 Million EUR | 0.0% |
| 2013 Q4 | 32.44 Million EUR | 4.31% |
| 2013 Q3 | 31.1 Million EUR | 1.3% |
| 2013 FY | - EUR | 12.03% |
| 2012 FY | - EUR | 23.35% |
| 2012 Q2 | 23.2 Million EUR | 0.0% |
| 2011 Q2 | 17.6 Million EUR | 0.0% |
| 2011 FY | - EUR | 15.98% |
| 2010 FY | - EUR | 16.27% |
| 2010 Q2 | 16.8 Million EUR | 0.0% |
| 2009 FY | - EUR | 29.72% |
| 2008 FY | - EUR | 88.72% |
| 2007 FY | - EUR | -55.19% |
| 2006 FY | - EUR | 21.36% |
| 2005 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Medical Technologies Inc. | -963.95 Thousand USD | 78495.857% |
| Ansell Limited | 209.86 Million USD | -260.095% |
| Ansell Limited | 206.3 Million USD | -266.311% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 42.83 Million USD | -1664.014% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -1.62 Million USD | 46606.018% |
| Psykey, Inc. | -1.29 Million USD | 58441.517% |
| ConvaTec Group Plc | 455.5 Million USD | -65.906% |
| ConvaTec Group Plc | 455.5 Million USD | -65.906% |
| Encision Inc. | -544.19 Thousand USD | 138965.664% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 532996.129% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 687537.46% |
| Innovative MedTech Inc. | -7.67 Million USD | 9947.772% |
| LifePoint, Inc. | -14.2 Million USD | 5421.03% |
| Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 12314.32% |
| Paradigm Medical Industries, Inc. | -325 Thousand USD | 232623.077% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -215.23 Thousand USD | 351206.238% |
| Reflect Scientific, Inc. | -405.78 Thousand USD | 186332.084% |
| SmileDirectClub, Inc. | -186.13 Million USD | 505.987% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | -68.749% |
| SheerVision, Inc. | -110.53 Thousand USD | 683799.596% |
| United Health Products, Inc. | -2.5 Million USD | 30301.254% |
| Vasamed, Inc. | -4.57 Million USD | 16620.048% |
| Wearable Health Solutions, Inc. | -2.26 Million USD | 33527.167% |
| Yubo International Biotech Limited | -1.17 Million USD | 64268.208% |